A new study finds breast cancer survivors in general have higher risk of new cancer diagnosis compared to healthy individuals. The article, which appears in CANCER, states that compared to the general population in the United States, the risk of new cancer diagnoses among survivors was 20% higher for those with hormone receptor (HR) positive cancers and 44% higher for those with HR-negative cancers. Breast cancer is the most commonly diagnosed and prevalent cancer among women in the U.S., with over 3.9 million living breast cancer survivors as of 2019. The number of survivors is expected to increase with the aging population and advances in breast cancer treatment. Subsequent primary cancer (SPC) after breast cancer is a well-known late effect, but the risk by breast cancer subtype and age at diagnosis was largely unknown except for contralateral breast, lung, and ovarian cancers. This study, led by Hyuna Sung, PhD, is the first to examine the risk of a range of SPCs including 26 types, and evaluate the risk by tumor subtypes and diagnosis age of breast cancer. This study included women (aged 20 to 84 years) diagnosed with invasive breast cancer from 1992-2015 and who survived for a year or more.
Radiation Oncologists Met With Congressional Leaders to Reverse CMS Cuts and Provide Equal Access to Care
Radiation oncologists met with Congress to urge leaders to consider how the Medicare and Medicaid Services (CMS) proposal to make significant cuts to radiation oncology facilities could be detrimental to the survival of patients with Read more…
FDA Approves Neoadjuvant Pembrolizumab Combination for Early TNBC Indication
The FDA granted approval to the supplemental biologics license application (sBLA) for pembrolizumab (Keytruda) as neoadjuvant therapy for patients with high-risk early-stage triple-negative breast cancer (TNBC) when given in combination with chemotherapy followed by single-agent Read more…
Recommended TVUS Screening Thresholds May Miss Endometrial Cancer in Black Women
Adherence to current clinical guidelines for the evaluation of postmenopausal bleeding may result in systematic underdiagnosis of endometrial cancer (EC) in Black women, according to a study published online July 15 in JAMA Oncology. Kemi M. Read more…